Hello! You are part of a community of millions who seek out Democracy Now! each month for ad-free daily news you can trust. Maybe you come for our daily headlines. Maybe you come for our in-depth stories that expose corporate and government abuses of power and lift up the voices of ordinary people working to make change in extraordinary times. We produce all of this news at a fraction of the budget of a commercial news operation. We do this without ads, government funding or corporate sponsorship. How? This model of news depends on support from viewers and listeners like you. Today, less than 1% of our visitors support Democracy Now! with a donation each year. If even 3% of our website visitors donated just $10 per month, we could cover our basic operating expenses for a year. Pretty amazing right? If you visit us daily or weekly or even just once a month, now is a great time to make a monthly contribution.

Your Donation: $
Friday, July 23, 1999 FULL SHOW | HEADLINES | NEXT: War and Peace Report
1999-07-23

South Africa and AIDS Drugs

download:   Audio Get CD/DVD More Formats
DONATE →
This is viewer supported news

A prescription medicine bill that would have allowed South Africa to produce inexpensive generic AIDS drugs (at 10% of the cost of AIDS drugs produced in the West) has been struck down by an appeals court. The United States and other Western countries say they oppose the bill because of a clause that could authorize the Government to ignore international drug patents. However, the court struck it down only on a technicality, ruling it had been promulgated prematurely.

Guest:

  • Jamie Love, Consumer Project On Technology

Related link:

Recent Shows More

Full News Hour

Stories


Creative Commons License The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to democracynow.org. Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.